A Study of the Mechanism of Inhibition of Fibrinolysis by Activated Thrombin-activable Fibrinolysis Inhibitor*

TAFI (thrombin-activable fibrinolysis inhibitor) is a recently described plasma zymogen that, when exposed to the thrombin-thrombomodulin complex, is converted by proteolysis at Arg92 to a basic carboxypeptidase that inhibits fibrinolysis (TAFIa). The studies described here were undertaken to elucidate the molecular basis for the inhibition of fibrinolysis. When TAFIa is included in a clot undergoing fibrinolysis induced by tissue plasminogen activator and plasminogen, the time to achieve lysis is prolonged, and free arginine and lysine are released over time. In addition, TAFIa prevents a 2.5-fold increase in the rate constant for plasminogen activation which occurs when fibrin is modified by plasmin in the early course of fibrin degradation. The effect is specific for the Glu- form of plasminogen. TAFIa prevents or at least attenuates positive feedback expressed through Lys-plasminogen formation during the process of fibrinolysis initiated by tissue plasminogen activator and plasminogen. TAFIa also inhibits plasmin activity in a clot and prolongs fibrinolysis initiated with plasmin. We conclude that TAFIa suppresses fibrinolysis by removing COOH-terminal lysine and arginine residues from fibrin, thereby reducing its cofactor functions in both plasminogen activation and the positive feedback conversion of Glu-plasminogen to Lys-plasminogen. At relatively elevated concentrations, it also directly inhibits plasmin.

[1]  V. Gurewich,et al.  The effect of the carboxy-terminal lysine of urokinase on the catalysis of plasminogen activation. , 1991, Thrombosis research.

[2]  B. Norrman,et al.  Fibrinolysis mediated by tissue plasminogen activator. Disclosure of a kinetic transition. , 1985, European journal of biochemistry.

[3]  D. Hendriks,et al.  Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen. , 1994, The Journal of biological chemistry.

[4]  E. Vellenga,et al.  The mutual relationship between the two molecular forms of the major fibrinolysis inhibitor alpha-2-antiplasmin in blood. , 1986, Blood.

[5]  A. Horrevoets,et al.  A Steady-state Template Model That Describes the Kinetics of Fibrin-stimulated [Glu1]- and [Lys78]Plasminogen Activation by Native tissue-type Plasminogen Activator and Variants That Lack Either the Finger or Kringle-2 Domain* , 1997, The Journal of Biological Chemistry.

[6]  D. Eaton,et al.  Activation and characterization of procarboxypeptidase B from human plasma. , 1995, Biochemistry.

[7]  D. Drayna,et al.  Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. , 1991, The Journal of biological chemistry.

[8]  R. Chalkley,et al.  High resolution acrylamide gel electrophoresis of histones. , 1969, Archives of biochemistry and biophysics.

[9]  S. Scharpe,et al.  Purification and characterization of a new arginine carboxypeptidase in human serum. , 1990, Biochimica et biophysica acta.

[10]  E. Angles-cano,et al.  Characterization of the binding of plasminogen to fibrin surfaces: the role of carboxy-terminal lysines. , 1991, Biochemistry.

[11]  M. Meldal,et al.  The role of fragment X polymers in the fibrin enhancement of tissue plasminogen activator-catalyzed plasmin formation. , 1990, Journal of Biological Chemistry.

[12]  G. Hortin,et al.  Alpha 2-antiplasmin's carboxy-terminal lysine residue is a major site of interaction with plasmin. , 1988, Biochemical and biophysical research communications.

[13]  H. Okada,et al.  An arginine specific carboxypeptidase generated in blood during coagulation or inflammation which is unrelated to carboxypeptidase N or its subunits. , 1989, Biochemical and biophysical research communications.

[14]  E. Plow,et al.  On the Mechanism of the Antifibrinolytic Activity of Plasma Carboxypeptidase B* , 1997, The Journal of Biological Chemistry.

[15]  E. Topol,et al.  Inducible carboxypeptidase activity. A role in clot lysis in vivo. , 1996, Circulation.

[16]  C. D. de Vries,et al.  Identification of the domains of tissue-type plasminogen activator involved in the augmented binding to fibrin after limited digestion with plasmin. , 1989, The Journal of biological chemistry.

[17]  D. Rijken,et al.  Superficial accumulation of plasminogen during plasma clot lysis. , 1995, Circulation.

[18]  V. Gurewich,et al.  Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained. , 1988, The Journal of clinical investigation.

[19]  K. Higashino,et al.  Enzymic determination of L-lysine in biological materials. , 1972, Analytical biochemistry.

[20]  Jordi Félez,et al.  Role of cell-surface lysines in plasminogen binding to cells: identification of alpha-enolase as a candidate plasminogen receptor. , 1991, Biochemistry.

[21]  J. Morser,et al.  TAFI, or Plasma Procarboxypeptidase B, Couples the Coagulation and Fibrinolytic Cascades through the Thrombin-Thrombomodulin Complex* , 1996, The Journal of Biological Chemistry.

[22]  O. Miura,et al.  Human alpha 2-plasmin inhibitor. , 1993, Methods in enzymology.

[23]  M. Nesheim,et al.  Purification and Characterization of TAFI, a Thrombin-activable Fibrinolysis Inhibitor (*) , 1995, The Journal of Biological Chemistry.

[24]  D. Eaton,et al.  Plasma carboxypeptidases as regulators of the plasminogen system. , 1995, The Journal of clinical investigation.

[25]  A. Horrevoets,et al.  Production and Characterization of Recombinant Human Plasminogen(S741C-Fluorescein) , 1997, The Journal of Biological Chemistry.

[26]  J. Morser,et al.  Both Cellular and Soluble Forms of Thrombomodulin Inhibit Fibrinolysis by Potentiating the Activation of Thrombin-activable Fibrinolysis Inhibitor* , 1998, The Journal of Biological Chemistry.

[27]  M. Grieshaber,et al.  A rapid and specific enzymatic method for the estimation of L-Arginine. , 1975, Analytical biochemistry.

[28]  M. Boffa,et al.  Plasma and Recombinant Thrombin-activable Fibrinolysis Inhibitor (TAFI) and Activated TAFI Compared with Respect to Glycosylation, Thrombin/Thrombomodulin-dependent Activation, Thermal Stability, and Enzymatic Properties* , 1998, The Journal of Biological Chemistry.

[29]  K. Mann,et al.  Interactions of a fluorescent active-site-directed inhibitor of thrombin: dansylarginine N-(3-ethyl-1,5-pentanediyl)amide. , 1979, Biochemistry.

[30]  G. Broze,et al.  Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma. , 1996, Blood.

[31]  S. Thorsen,et al.  The course and prerequisites of Lys-plasminogen formation during fibrinolysis. , 1988, Biochemistry.

[32]  M. Nesheim,et al.  The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. , 1996, Blood.

[33]  M. Nesheim,et al.  Lys-plasminogen is a significant intermediate in the activation of Glu-plasminogen during fibrinolysis in vitro. , 1992, The Journal of biological chemistry.